Prospective Grant of Co-Exclusive License: Prevention and Treatment of Human Cancer and Tumors by Inhibitors of Any or All of the Adenosine Receptor Subtypes Covered by the Licensed Patent Rights, 4284-4285 [E7-1376]
Download as PDF
<![CDATA[
4284
Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices
93.393–93.396, 93.837–93.844, 93.846–
93.878, 93.892, 93.893, National
Institutes of Health, HHS).
Dated: January 18, 2007.
David Clary,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–368 Filed 1–29–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Use of Inhaled Nitrite Therapy
for the Treatment of Pulmonary
Conditions
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
ycherry on PROD1PC64 with NOTICES
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of an exclusive
license to practice the invention
embodied in: PCT patent applications
PCT/US2004/21985 and PCT/US2004/
22232, filed July 9, 2004, both entitled
‘‘Use of Nitrite Salts for the Treatment
of Cardiovascular Conditions’’ [HHS
Reference Number: E–254–2003/2–3–
PCT–01], to Aires Pharmaceuticals, Inc.,
a portfolio company of ProQuest
Investments LLC, Princeton, N.J. The
field of use of inhaled administration of
nitrite salts for this exclusive license
may be limited to the use of inhaled
formulations of nitrite salts for the
treatment of Pulmonary Hypertension
and pulmonary and/or cardiopulmonary
conditions. The United States of
America is an assignee of the patent
rights in these inventions.
DATES: Only written comments and/or
application for a license, which are
received by the NIH Office of
Technology Transfer on or before April
2, 2007 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Susan Carson, D.Phil., Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
E-mail: carsonsu@od.nih.gov;
Telephone: (301) 435–5020; Facsimile:
(301) 402–0220.
SUPPLEMENTARY INFORMATION: The core
invention is the unexpected finding that
VerDate Aug<31>2005
15:36 Jan 29, 2007
Jkt 211001
low, physiological and non-toxic
concentrations of sodium nitrite are able
to increase blood flow and produce
vasodilation by infused and nebulized
routes of administration. Pulmonary
Hypertension (PH) occurs as a primary
or idiopathic disease as well as
secondary to a number of pulmonary
and systemic diseases, such as neonatal
PH and sickle cell disease. There is no
cure for pulmonary hypertension, a
nitric-oxide deficient state characterized
by pulmonary vasoconstriction and
systemic hypoxemia and therapies vary
in efficacy and cost. Recent studies by
NIH researchers and their collaborators
provided evidence that the blood anion
nitrite contributes to hypoxic
vasodilation through a heme-based,
nitric oxide (NO)-generating reaction
with deoxyhemoglobin and potentially
other heme proteins [Nature Medicine
2003 9: 1498–1505]. These initial results
indicate that sodium nitrite can be used
as a potential cost-effective platform
therapy for a wide variety of disease
indications characterized broadly by
constricted blood flow or hypoxia.
These results have been further
corroborated by work in the neonatal
lamb model for PH. Inhaled sodium
nitrite delivered by aerosol to newborn
lambs with hypoxic pulmonary
hypertension elicited a rapid and
sustained reduction (65%) in hypoxiainduced pulmonary hypertension.
Pulmonary vasodilation elicited by
aerosolized nitrite was
deoxyhemoglobin- and pH-dependent
and was associated with increased
blood levels of iron-nitrosylhemoglobin. Notably, short term
delivery of nitrite dissolved in saline
through nebulization produced
selective, sustained pulmonary
vasodilation with no clinically
significant increase in blood
methemoglobin levels. [Nature
Medicine 2004 10: 1122–1127]. Method
of use claims for nitrite salt
formulations are directed to conditions
associated with high blood pressure,
decreased blood flow and for the
treatment of specific conditions such as
pulmonary hypertension and other
indications.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within 60 days from the date of this
published Notice, NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications
for a license filed in response to this
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: January 22, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–1378 Filed 1–29–07; 8:45 am]
BILLING CODE 4140–04–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Co-Exclusive
License: Prevention and Treatment of
Human Cancer and Tumors by
Inhibitors of Any or All of the
Adenosine Receptor Subtypes
Covered by the Licensed Patent Rights
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services, is
contemplating the grant of a coexclusive license to practice the
invention embodied in Patent
Applications U.S. 60/340,772, filed on
12/12/2001, U.S. 60/342,582, filed on
12/19/2001, PCT/US2002/036829, filed
on 11/14/2002, and corresponding EP,
CA, AU, and JP filings, as well as U.S.
10/498,416, filed on 06/10/2004;
entitled ‘‘Methods for using
extracellular adenosine inhibitors and
adenosine receptor inhibitors to
enhance immune response and
inflammation’’, all by Michail V.
Sitkovsky, and Akio Ohta, to Redox
Therapies, Inc., having a place of
business in Boston, MA. The patent
rights in this invention have been
assigned to the United States of
America.
DATES: Only written comments and/or
application for a license that are
received by the NIH Office of
Technology Transfer on or before April
2, 2007 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Cristina Thalhammer-Reyero, Ph.D.,
M.B.A., Office of Technology Transfer,
E:\FR\FM\30JAN1.SGM
30JAN1
Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices
National Institutes of Health, 6011
Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; E-mail:
ThalhamC@mail.nih.gov; Telephone:
301–435–4507; Facsimile: 301–402–
0220.
The
prospective co-exclusive license will be
royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within 60 days from the date of this
published Notice, NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
The technology described and
claimed in the subject invention relates
to methods to enhance and prolong the
body’s immune response as well as to
promote targeted tissue damage, such as
for tumor destruction, by inhibiting
signaling through the adenosine
receptor. The inventors have shown that
adenosine A2a and A3a receptors play
a critical and non-redundant role in
down-regulation of inflammation in
vivo by acting as the physiological
termination mechanism that can limit
the immune response. The methods
described involve administering either
an adenosine-degrading drug or an
adenosine receptor antagonist to exert a
more effective and durable immune
response and inflammation, and more
specifically to the subject exclusive
license application, to reduce the size of
tumors. Furthermore, using the claimed
method in combination with
conventional anti tumor agent can be an
effective treatment against cancer.
The invention has potential
applications in the many markets in
which therapeutic and preventive uses
of manipulating the adenosine pathway
are involved, including the regulation of
hypoxia, tissue damage, tumor
destruction, inflammation, increasing
the efficacy of vaccines, and other
immune responses.
This invention is further described in
Ohta A et al., ‘‘Role of G-proteincoupled adenosine receptors in downregulation of inflammation and
protection from tissue damage,’’ Nature
2001 Dec 20–27; 414(6866):916–20.
The field of use may be limited to
‘‘Prevention and treatment of human
cancer and tumors by inhibitors of any
or all of the adenosine receptor subtypes
covered by the Licensed Patent Rights’’.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
ycherry on PROD1PC64 with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Aug<31>2005
15:36 Jan 29, 2007
Jkt 211001
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
This announcement is a supplement
to the one published in the Federal
Register on April 11, 2005 (70 FR
18419).
Dated: January 18, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–1376 Filed 1–29–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Privacy Office; Published Privacy
Impact Assessments on the Web
Privacy Office, Office of the
Secretary, Department of Homeland
Security.
ACTION: Notice of Publication of Privacy
Impact Assessments.
AGENCY:
SUMMARY: The Privacy Office of the
Department of Homeland Security is
making available four Privacy Impact
Assessments on various programs and
systems in the Department. These
assessments were approved and
published on the Privacy Office’s Web
site between December 1, 2006 and
December 31, 2006.
DATES: The Privacy Impact Assessments
will be available on the DHS Web site
until April 2, 2007, after which they
may be obtained by contacting the DHS
Privacy Office (contact information
below).
FOR FURTHER INFORMATION CONTACT:
Hugo Teufel III, Chief Privacy Officer,
Department of Homeland Security,
Washington, DC 20528; by telephone
(571) 227–3813, facsimile (866) 466–
5370, or e-mail: pia@dhs.gov.
SUPPLEMENTARY INFORMATION: Between
December 1, 2006 and December 31,
2006, the Chief Privacy Officer of the
Department of Homeland Security
(DHS) approved and published four
Privacy Impact Assessments (PIAs) on
the DHS Privacy Office Web site,
https://www.dhs.gov/privacy, under the
link for ‘‘Privacy Impact Assessments.’’
Below is a short summary of each of
those systems, indicating the DHS
component responsible for the system,
and the date on which the PIA was
approved. Additional information can
be found on the Web site or by
contacting the Privacy Office.
1. System: DisasterHelp.gov.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
4285
Component: Science and Technology.
Date of approval: December 19, 2006.
The DisasterHelp.Gov (DHelp) Web
site or Web portal is operated by the
Science and Technology Directorate of
the Department of Homeland Security. It
is intended to assist political and civil
service leadership, emergency
managers, homeland security advisors,
and first responders in the execution of
their disaster management
responsibilities. The information on this
Web site will be used to enhance
disaster management on an interagency
and intergovernmental basis by helping
users find information and services. The
types of personally identifiable
information used will include contact
information for these individuals. The
collection of this personally identifiable
information is the reason for this
privacy impact assessment.
2. System: Alien Flight Student
Program (Amended).
Component: Transportation Security
Administration.
Date of approval: December 22, 2006.
The Transportation Security
Administration (TSA) will collect
personal information about flighttraining candidates to conduct the
security threat assessments on alien
flight students required by the Aviation
and Transportation Security Act and
section 612 of Vision 100—Century of
Aviation Reauthorization Act. For pilots
seeking recurrent training, the Alien
Flight Student Program will verify
eligibility for such training. TSA is
amending the PIA originally published
in June 2004 to reflect certain updates
after periodic review, including its use
of commercial data for identity
verification purposes, and the
promulgation of an applicable record
retention schedule.
3. System: Threat Assessment for
Airport Badge and Credential Holders.
Component: Transportation Security
Administration.
Date of approval: December 20, 2006.
TSA is amending the PIA for the
Security Threat Assessment for Airport
Badge and Credential Holders to reflect
an expansion of the covered population.
Recently amended airport security
directives now require that each
individual to whom an airport issues an
identification badge or credentials
undergo a security threat assessment
regardless of the level of unescorted
access permitted the individual. Namebased security threat assessments will
be performed on all individuals seeking
or holding airport identification badges
or credentials. Fingerprint-based
criminal history checks, in addition to
the name-based security threat
assessments, will continue to be
E:\FR\FM\30JAN1.SGM
30JAN1
]]>Agencies
[Federal Register Volume 72, Number 19 (Tuesday, January 30, 2007)]
[Notices]
[Pages 4284-4285]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-1376]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Co-Exclusive License: Prevention and
Treatment of Human Cancer and Tumors by Inhibitors of Any or All of the
Adenosine Receptor Subtypes Covered by the Licensed Patent Rights
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
a co-exclusive license to practice the invention embodied in Patent
Applications U.S. 60/340,772, filed on 12/12/2001, U.S. 60/342,582,
filed on 12/19/2001, PCT/US2002/036829, filed on 11/14/2002, and
corresponding EP, CA, AU, and JP filings, as well as U.S. 10/498,416,
filed on 06/10/2004; entitled ``Methods for using extracellular
adenosine inhibitors and adenosine receptor inhibitors to enhance
immune response and inflammation'', all by Michail V. Sitkovsky, and
Akio Ohta, to Redox Therapies, Inc., having a place of business in
Boston, MA. The patent rights in this invention have been assigned to
the United States of America.
DATES: Only written comments and/or application for a license that are
received by the NIH Office of Technology Transfer on or before April 2,
2007 will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Cristina Thalhammer-Reyero, Ph.D., M.B.A.,
Office of Technology Transfer,
[[Page 4285]]
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, MD 20852-3804; E-mail: ThalhamC@mail.nih.gov; Telephone:
301-435-4507; Facsimile: 301-402-0220.
SUPPLEMENTARY INFORMATION: The prospective co-exclusive license will be
royalty bearing and will comply with the terms and conditions of 35
U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be
granted unless, within 60 days from the date of this published Notice,
NIH receives written evidence and argument that establishes that the
grant of the license would not be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
The technology described and claimed in the subject invention
relates to methods to enhance and prolong the body's immune response as
well as to promote targeted tissue damage, such as for tumor
destruction, by inhibiting signaling through the adenosine receptor.
The inventors have shown that adenosine A2a and A3a receptors play a
critical and non-redundant role in down-regulation of inflammation in
vivo by acting as the physiological termination mechanism that can
limit the immune response. The methods described involve administering
either an adenosine-degrading drug or an adenosine receptor antagonist
to exert a more effective and durable immune response and inflammation,
and more specifically to the subject exclusive license application, to
reduce the size of tumors. Furthermore, using the claimed method in
combination with conventional anti tumor agent can be an effective
treatment against cancer.
The invention has potential applications in the many markets in
which therapeutic and preventive uses of manipulating the adenosine
pathway are involved, including the regulation of hypoxia, tissue
damage, tumor destruction, inflammation, increasing the efficacy of
vaccines, and other immune responses.
This invention is further described in Ohta A et al., ``Role of G-
protein-coupled adenosine receptors in down-regulation of inflammation
and protection from tissue damage,'' Nature 2001 Dec 20-27;
414(6866):916-20.
The field of use may be limited to ``Prevention and treatment of
human cancer and tumors by inhibitors of any or all of the adenosine
receptor subtypes covered by the Licensed Patent Rights''.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
This announcement is a supplement to the one published in the
Federal Register on April 11, 2005 (70 FR 18419).
Dated: January 18, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-1376 Filed 1-29-07; 8:45 am]
BILLING CODE 4140-01-P
